ARTICLE | Clinical News
Idec begins Phase II with IDEC-131
January 29, 2001 8:00 AM UTC
IDPH began a dose-escalation Phase II trial of its IDEC-131 humanized anti-CD-154 (CD40L) antibody to treat moderate to severe psoriasis. Eisai (Tokyo, Japan) has rights to IDEC-131 in Europe and Asia...